|
Xenova is to acquire Cantab Pharmaceuticals, the Cambridge-based vaccines company, for £53m. 20-Feb-2001 Cantab Pharmaceuticals is to conduct a strategic review that is expected to lead to the company being put up for sale by the end of the year. 27-Oct-2000 Cantab Pharmaceuticals is in talks to acquire Peptide Therapeutics, the Cambridge-based biotechnology company, for about £80m, in order to create the largest independent vaccines group in Europe. 27-Jul-2000 Cantab Pharmaceuticals is seeking acquisitions in order to boost its product development pipeline, and is already in discussions with one or two companies. 16-Jun-2000 Cantab Pharmaceuticals is opening a new corporate headquarters on Cambridge Science Park. 15-Jul-1999 Cantab Pharmaceuticals is forming an alliance with ImmuLogic Pharmaceutical of the US to develop vaccines against nicotine and cocaine. 22-Dec-1998 Cantab Pharmaceuticals is planning to increase its range of drugs under development and will raise the number of staff from 100 to 125 with a new research facility. 20-Mar-1997 Glaxo Wellcome is acquiring a 4% stake in Cantab Pharmaceuticals for £6m, and paying £5m for the worldwide rights to market Cantab's Disc HSV treatment for genital herpes. 19-Mar-1997 Cantab Pharmaceuticals has been given FDA approval for human trials of its Disc (disabled, infective, single cycle) virus technology. 03-Dec-1996 Cantab Pharmaceuticals, the biotechnology concern, plans to raise £25m in a share placing to increase production capacity and speed up the development of at least one product. 15-May-1996
|